IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties

Jagadeesh Bayry¹, Hans-Peter Hartung², Srini V Kaveri³

Affiliations

¹ Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris F-75006, France; International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohematology, Mumbai 400012, India. Electronic address: jagadeesh.bayry@crc.jussieu.fr.
² Department of Neurology, Medical Faculty, Heinrich Heine University, Moorenstr. 5, D-40225 Düsseldorf, Germany.
³ Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris F-75006, France; International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohematology, Mumbai 400012, India.

PMID: 26003802
DOI: 10.1016/j.tips.2015.04.012

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties

Jagadeesh Bayry et al. Trends Pharmacol Sci. 2015 Jul.

. 2015 Jul;36(7):419-21.

doi: 10.1016/j.tips.2015.04.012. Epub 2015 May 20.

Authors

Jagadeesh Bayry¹, Hans-Peter Hartung², Srini V Kaveri³

Affiliations

¹ Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris F-75006, France; International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohematology, Mumbai 400012, India. Electronic address: jagadeesh.bayry@crc.jussieu.fr.
² Department of Neurology, Medical Faculty, Heinrich Heine University, Moorenstr. 5, D-40225 Düsseldorf, Germany.
³ Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris F-75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathology and Therapeutic Immunointervention, Paris F-75006, France; Sorbonne Universités, UPMC University Paris 06, UMR S 1138, Paris F-75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris F-75006, France; International Associated Laboratory IMPACT (Institut National de la Santé et de la Recherche Médicale, France - Indian Council of Medical Research, India), National Institute of Immunohematology, Mumbai 400012, India.

PMID: 26003802
DOI: 10.1016/j.tips.2015.04.012

Abstract

Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing-remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.

Keywords: IVIg; autoimmunity; biomarkers; immunotherapy; inflammation; multiple sclerosis.

PubMed Disclaimer

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties

Affiliations

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Miscellaneous